Nuvalent's $10.6B sale to GSK clears a key antitrust hurdle as the HSR waiting period expires
NUVL sits 74% above its 52-week low of $71.13.
Summary
Nuvalent disclosed that the HSR waiting period for its $10.6 billion acquisition by GSK expired on July 9, 2026, satisfying a key antitrust condition. The tender offer of $124 per share remains subject to other closing conditions.
Key Events · M&A and Partnerships · NUVL
-
HSR Waiting Period Expires
The required waiting period under the HSR Act expired at 11:59 p.m. ET on July 9, 2026, satisfying the antitrust condition for GSK's tender offer.
-
Deal Remains Subject to Other Conditions
While antitrust clearance removes a significant regulatory risk, the Offer and Merger still require other customary closing conditions.
-
Tender Offer Price Unchanged
GSK's all-cash offer of $124.00 per share remains in effect, representing a premium to Nuvalent's pre-announcement trading price.
-
Next Steps Toward Closing
With HSR clearance obtained, the parties can proceed toward satisfying remaining conditions and closing the transaction.
Analysis · NUVL · Life Sciences
With the HSR waiting period now expired, a major regulatory condition for GSK's $124/share all-cash tender offer has been removed. Antitrust clearance significantly de-risks the path to closing, though other customary conditions remain. This milestone marks a critical step forward in the acquisition process.
At the time of this filing, NUVL was trading at $123.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $71.13 to $123.86. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.